AGEX iTR1547
Alternative Names: AGEX-iTR1547Latest Information Update: 29 Mar 2024
At a glance
- Originator AgeX Therapeutics
- Developer Serina Therapeutics
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Wounds
- No development reported Heart failure